neumentum | Media Room | PressRelease.com

Tagged neumentum

Neumentum Announces Initiation of Phase 3 Program Evaluating Its Lead Product Candidate, NTM-001, for the Management of Moderately Severe Acute Pain

Press Release Jan 25, 2023

Neumentum Announces Initiation of Phase 3 Program Evaluating Its Lead Product Candidate, NTM-001, for the Management of Moderately Severe Acute Pain

NTM-001 is an Investigational, Alcohol-Free, Stable Formulation of Ketorolac in a Pre-Mixed Bag for 24h Continuous Infusion. NTM-001 has the Potential to Deliver Opioid-Level Pain Relief Without Analgesic Gaps and Reduce or Eliminate the Need for Opioids. Phase 3 Efficacy and Safety Study is Comparing NTM-001 vs. Placebo, and Includes a Morphine Arm for Assay Sensitivity in Patients with Moderately Severe Pain After Bunionectomy Surgery. Results Expected Second Half 2023. Read More

First
Prev

1

Next
Last